Innovation in the Treatment of Thoracic Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 2469

Special Issue Editors


E-Mail Website
Guest Editor
Robotic Multispecialty Center for Surgery Robotic, Minimally Invasive Thoracic Surgery, University of Pisa, 56124 Pisa, Italy
Interests: lung cancer; robotic surgery; mediastinal and thymus surgery; pleural surgery

E-Mail Website
Guest Editor
Minimally Invasive and Robotic Thoracic Surgery, Robotic Multispecialty Center of Surgery, University Hospital of Pisa, Pisa, Italy
Interests: lung cancer; mediastinum; minimally invasive surgery; pleural malignancy; robotic surgery
Special Issues, Collections and Topics in MDPI journals
Department of Surgical, Medical, Molecular Pathology and Critical Area, Anatomic Pathology Section, 56126 Pisa, Italy
Interests: lung cancer; malignant pleural mesothelioma; molecular pathology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Minimally Invasive and Robotic Thoracic Surgery, Robotic Multispecialty Center of Surgery, University Hospital of Pisa, 56124 Pisa, Italy
Interests: : lung cancer surgery; robotic surgery mediastinal and thymus surgery; pleural surgery

E-Mail Website
Guest Editor
Department of Surgical, Medical and Molecular Pathology and Critical Area Medicine, Azienda Ospedaliero-Universitaria Pisana, 56125 Pisa, Italy
Interests: lung cancer; thoracic malignancies; chemotherapy; immunotherapy; targeted therapies; molecular profiling; personalized medicine

Special Issue Information

Dear Colleagues,

 In the last years, we have been spectators of an evolution in the field of thoracic tumors treatment.

In oncologic area, target therapies and immunotherapy are modifying the disease course, obtaining an improvement of prognosis. Moreover, loco-regional treatments are focusing on increasingly minimally invasive approaches. Certainly, the innovation is the foundation of these important changes, with an impact on medical practice, patient prognosis and quality of life.

We are pleased to invite you to participate to this Special Issue on the innovation in the treatment of thoracic cancers. This special issue aims to give an overview of the most recent innovation in surgical, oncological, pathological and radiotherapy field in the treatment of lung, pleural and mediastinal tumors.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: new surgical techniques, additional application of surgical approaches, targeted and biomarker-driven treatments, precision medicine, innovation in pathological analysis, future directions in radiotherapy and technological evolution in cancer therapy.

We look forward to receiving your contributions.

Prof. Dr. Franca Melfi
Dr. Carmelina C. Zirafa
Dr. Greta Alì
Dr. Gaetano Romano
Dr. Andrea Sbrana
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung tumors 
  • mediastinal tumors 
  • pleural malignancies 
  • target therapies 
  • surgical techniques 
  • innovation - precision medicine

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 1496 KiB  
Article
Validation of a Gene Expression Approach for the Cytological Diagnosis of Epithelioid and Biphasic Pleural Mesothelioma on a Consecutive Series
by Rossella Bruno, Anello Marcello Poma, Greta Alì, Agnese Proietti, Alessandro Ribechini, Antonio Chella and Gabriella Fontanini
Cancers 2023, 15(23), 5534; https://doi.org/10.3390/cancers15235534 - 22 Nov 2023
Viewed by 849
Abstract
Cytological diagnosis of pleural mesothelioma (PM) is controversial, even using ancillary markers (BAP1, MTAP and CDKN2A). Here, we aimed to prospectively validate a previously developed 117-gene expression panel for the differential cytological diagnosis of epithelioid, biphasic PM and mesothelial hyperplasia. Seventy-seven pleural effusions [...] Read more.
Cytological diagnosis of pleural mesothelioma (PM) is controversial, even using ancillary markers (BAP1, MTAP and CDKN2A). Here, we aimed to prospectively validate a previously developed 117-gene expression panel for the differential cytological diagnosis of epithelioid, biphasic PM and mesothelial hyperplasia. Seventy-seven pleural effusions were classified using the 117-gene expression levels (NanoString system). Sixty-eight cases were also screened for ancillary markers. The performance of both gene panel and ancillary markers was evaluated using ROC metrics. A score using the top consistently deregulated genes between epithelioid and biphasic PM was built to subtype malignant effusions. The panel alone reached a diagnostic accuracy (0.89) comparable to the best marker combination (BAP1 plus MTAP: 0.88). Ancillary tests missed 8 PMs, 7 of which were correctly classified by the panel. The score built by averaging the expression levels of MSLN, CLDN15 and CFB showed an accuracy of 0.80 in subtyping epithelioid and biphasic effusions. The 117-gene panel is effective for PM cytological diagnosis of epithelioid and biphasic PM. This tool can be complementary to ancillary markers, reducing invasive procedures and allowing an earlier diagnosis. Finally, the possibility to subtype PM on effusions strengthens the panel’s role in PM diagnosis and management. Full article
(This article belongs to the Special Issue Innovation in the Treatment of Thoracic Cancers)
Show Figures

Figure 1

Review

Jump to: Research

14 pages, 299 KiB  
Review
The Role of Lymphadenectomy in Early-Stage NSCLC
by Beatrice Manfredini, Carmelina Cristina Zirafa, Pier Luigi Filosso, Alessandro Stefani, Gaetano Romano, Federico Davini and Franca Melfi
Cancers 2023, 15(14), 3735; https://doi.org/10.3390/cancers15143735 - 23 Jul 2023
Cited by 4 | Viewed by 1145
Abstract
Lung cancer remains the leading cause of cancer-related death worldwide. The involvement of lymph nodes by the tumor has a strong impact on survival of patients. For this reason, lymphadenectomy plays a crucial role in the staging and prognosis of NSCLC, to define [...] Read more.
Lung cancer remains the leading cause of cancer-related death worldwide. The involvement of lymph nodes by the tumor has a strong impact on survival of patients. For this reason, lymphadenectomy plays a crucial role in the staging and prognosis of NSCLC, to define the most appropriate therapeutic strategies concerning the stage of the disease. To date, the benefit, in terms of survival, of the different extents of lymphadenectomy remains controversial in the scientific community. It is recognized that metastatic involvement of mediastinal lymph nodes in lung cancer is one of the most significant prognostic factors, in terms of survival, and it is therefore mandatory to identify patients with lymph node metastases who may benefit from adjuvant therapies, to prevent distant disease and local recurrences. The purpose of this review is to evaluate the role of lymphadenectomy in early-stage NSCLC in terms of efficacy and accuracy, comparing systematic, sampling, and lobe-specific lymph node dissection and analyzing the existing critical issue, through a search of the most relevant articles published in the last decades. Full article
(This article belongs to the Special Issue Innovation in the Treatment of Thoracic Cancers)
Back to TopTop